TORONTO, July 26, 2013 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation") today announced that Mr. Ian Lennox and Mr. Ed McCormack have
resigned as directors of the Corporation, effective August 1, 2013.
"Ian as Chairman of the Board of Directors, and Ed as Chairman of the
Finance and Audit Committee, have made significant contributions to
Spectral. They helped lead our transformation towards a therapeutic
focus and lead the process of funding our mission, and achieving IFRS
compliance. I am personally very grateful for their insights,
leadership and guidance over their many years as board members," said
Dr. Paul Walker, President and CEO of Spectral.
Anthony Bihl, Chairman of the Board of Directors added, "Ian and Ed
brought exceptional experience, insight, and value to the Spectral
Board, as they consistently focused on driving long term shareholder
value. Their contribution will be missed, and I thank them for all
they have done for Spectral."
The Nomination & Governance Committee will commence a board governance
review process to identify new directors for the board as well as the
composition of the committees of the board.
About Spectral Diagnostics
Spectral is a Phase III company seeking U.S. FDA approval for its lead
theranostics product (Toraymyxin) for the treatment of septic shock.
Toraymyxin is a therapeutic hemoperfusion device that removes
endotoxin, which can cause sepsis, from the bloodstream. Directed by
the Company's Endotoxin Activity Assay (EAA™), the only FDA-cleared
diagnostic for the risk of developing sepsis, Spectral's EUPHRATES
trial is the world's first theranostics trial in the area of sepsis.
Spectral is listed on the Toronto Stock Exchange under the symbol SDI,
and on the OTC QX under the symbol DIAGF. For more information please
SOURCE: Spectral Diagnostics Inc.
For further information:
Spectral Diagnostics Inc.
Executive Vice President and CFO
416-626-3233 ext. 2200
416-815-0700 ext. 225